Literature DB >> 25711465

Melatonin-mediated Bim up-regulation and cyclooxygenase-2 (COX-2) down-regulation enhances tunicamycin-induced apoptosis in MDA-MB-231 cells.

Seon Min Woo1, Kyoung-jin Min, Taeg Kyu Kwon.   

Abstract

Melatonin is involved in many physiological functions, and it has differential effects on apoptosis in normal and cancer cells. However, the mechanism of its antitumor roles is not well understood. In this study, we show that melatonin enhances tunicamycin-induced apoptosis in human breast carcinoma MDA-MB-231 cells. Melatonin up-regulates pro-apoptotic protein Bim expression at the transcriptional levels in the presence of tunicamycin. Melatonin inhibits tunicamycin-induced COX-2 expression in MDA-MB-231 cells. Furthermore, inhibition of COX-2 activity using the COX-2 inhibitor, NS398, increases tunicamycin-induced apoptosis. Interestingly, these effects were not associated with melatonin receptor signal pathways. Pertussis toxin (a general Gi protein inhibitor) or luzindole (a nonspecific melatonin receptor antagonist) did not reverse the effect of melatonin. In addition, melatonin blocked tunicamycin-induced NF-κB transcriptional activity, p65 nuclear translocation, and p38 MAPK activation. Melatonin-mediated p38 MAPK inhibition contributed to decreased COX-2 mRNA stability. Taken together, our results suggest that melatonin enhances antitumor function through up-regulation of Bim expression and down-regulation of COX-2 expression in tunicamycin-treated MDA-MB-231 cells.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COX-2; NF-κB; apoptosis; melatonin; p38 MAPK; tunicamycin

Mesh:

Substances:

Year:  2015        PMID: 25711465     DOI: 10.1111/jpi.12217

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  17 in total

Review 1.  Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization.

Authors:  B Farhood; N H Goradel; K Mortezaee; N Khanlarkhani; E Salehi; M S Nashtaei; H Mirtavoos-Mahyari; E Motevaseli; D Shabeeb; A E Musa; M Najafi
Journal:  Clin Transl Oncol       Date:  2018-08-22       Impact factor: 3.405

Review 2.  Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.

Authors:  Wamidh H Talib; Ahmad Riyad Alsayed; Alaa Abuawad; Safa Daoud; Asma Ismail Mahmod
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

Review 3.  Oral Mucositis: Melatonin Gel an Effective New Treatment.

Authors:  Ahmed Esmat Abdel Moneim; Ana Guerra-Librero; Javier Florido; Ying-Qiang Shen; Beatriz Fernández-Gil; Darío Acuña-Castroviejo; Germaine Escames
Journal:  Int J Mol Sci       Date:  2017-05-07       Impact factor: 5.923

Review 4.  Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.

Authors:  Russel J Reiter; Sergio A Rosales-Corral; Dun-Xian Tan; Dario Acuna-Castroviejo; Lilan Qin; Shun-Fa Yang; Kexin Xu
Journal:  Int J Mol Sci       Date:  2017-04-17       Impact factor: 5.923

5.  What is known about melatonin, chemotherapy and altered gene expression in breast cancer.

Authors:  Carlos Martínez-Campa; Javier Menéndez-Menéndez; Carolina Alonso-González; Alicia González; Virginia Álvarez-García; Samuel Cos
Journal:  Oncol Lett       Date:  2017-02-10       Impact factor: 2.967

6.  Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation.

Authors:  Li-Jia Bu; Han-Qing Yu; Lu-Lu Fan; Xiao-Qiu Li; Fang Wang; Jia-Tao Liu; Fei Zhong; Cong-Jun Zhang; Wei Wei; Hua Wang; Guo-Ping Sun
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

Review 7.  Melatonin as a potential anticarcinogen for non-small-cell lung cancer.

Authors:  Zhiqiang Ma; Yang Yang; Chongxi Fan; Jing Han; Dongjin Wang; Shouyin Di; Wei Hu; Dong Liu; Xiaofei Li; Russel J Reiter; Xiaolong Yan
Journal:  Oncotarget       Date:  2016-07-19

8.  Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway.

Authors:  Bin Yan; Aikepaer Wubuli; Yidong Liu; Xin Wang
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

9.  Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7/ CCL20 in glioma.

Authors:  Xueran Chen; Zhen Wang; Huihui Ma; Shangrong Zhang; Haoran Yang; Hongzhi Wang; Zhiyou Fang
Journal:  Oncotarget       Date:  2017-08-24

10.  Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway.

Authors:  Anli Yang; Fu Peng; Lewei Zhu; Xing Li; Shunling Ou; Zhongying Huang; Song Wu; Cheng Peng; Peng Liu; Yanan Kong
Journal:  Cell Death Dis       Date:  2021-07-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.